US20080312335A1 - Liver protection compounds of the cyclohexenone type from antrodia camphorata - Google Patents
Liver protection compounds of the cyclohexenone type from antrodia camphorata Download PDFInfo
- Publication number
- US20080312335A1 US20080312335A1 US11/902,599 US90259907A US2008312335A1 US 20080312335 A1 US20080312335 A1 US 20080312335A1 US 90259907 A US90259907 A US 90259907A US 2008312335 A1 US2008312335 A1 US 2008312335A1
- Authority
- US
- United States
- Prior art keywords
- liver
- compound
- cyclohexenone
- antrodia camphorata
- ccl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 64
- 241001486992 Taiwanofungus camphoratus Species 0.000 title claims abstract description 61
- 150000001875 compounds Chemical class 0.000 title claims abstract description 31
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 title abstract description 57
- 206010067125 Liver injury Diseases 0.000 claims abstract description 52
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 44
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 30
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims abstract description 24
- 108010082126 Alanine transaminase Proteins 0.000 claims abstract description 24
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims abstract description 24
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims abstract description 24
- 230000004761 fibrosis Effects 0.000 claims abstract description 23
- LJTSIMVOOOLKOL-UHFFFAOYSA-N 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyldodeca-2,6,10-trienyl)cyclohex-2-en-1-one Chemical compound COC1=C(OC)C(=O)C(C)C(CC=C(C)CCC=C(C)CCC=C(C)C)C1O LJTSIMVOOOLKOL-UHFFFAOYSA-N 0.000 claims abstract description 22
- 102000016938 Catalase Human genes 0.000 claims abstract description 21
- 108010053835 Catalase Proteins 0.000 claims abstract description 21
- LJTSIMVOOOLKOL-JAXLGGSGSA-N antroquinonolTM Natural products COC1=C(OC)C(=O)[C@@H](C)[C@H](CC=C(C)CCC=C(C)CCC=C(C)C)[C@H]1O LJTSIMVOOOLKOL-JAXLGGSGSA-N 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 10
- 102000006587 Glutathione peroxidase Human genes 0.000 claims abstract description 8
- 108700016172 Glutathione peroxidases Proteins 0.000 claims abstract description 8
- -1 cyclohexenone compound Chemical class 0.000 claims abstract description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 138
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 230000037396 body weight Effects 0.000 claims description 17
- 239000003960 organic solvent Substances 0.000 claims description 8
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000006286 aqueous extract Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052717 sulfur Chemical group 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 101001009581 Molluscum contagiosum virus subtype 1 Glutathione peroxidase Proteins 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 abstract description 14
- 230000003078 antioxidant effect Effects 0.000 abstract description 14
- 230000007423 decrease Effects 0.000 abstract description 13
- 239000000126 substance Substances 0.000 abstract description 10
- 230000001590 oxidative effect Effects 0.000 abstract description 5
- 231100000234 hepatic damage Toxicity 0.000 abstract description 4
- 230000008818 liver damage Effects 0.000 abstract description 4
- 241000700159 Rattus Species 0.000 description 52
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 24
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 24
- 229960004245 silymarin Drugs 0.000 description 24
- 235000017700 silymarin Nutrition 0.000 description 24
- 206010016654 Fibrosis Diseases 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 20
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- 239000013641 positive control Substances 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 13
- 231100000915 pathological change Toxicity 0.000 description 12
- 230000036285 pathological change Effects 0.000 description 12
- 238000000692 Student's t-test Methods 0.000 description 11
- 102000019197 Superoxide Dismutase Human genes 0.000 description 11
- 108010012715 Superoxide dismutase Proteins 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 229960003180 glutathione Drugs 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 150000003648 triterpenes Chemical class 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 238000012453 sprague-dawley rat model Methods 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000007882 cirrhosis Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010024636 Glutathione Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 231100000012 chronic liver injury Toxicity 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 231100000832 liver cell necrosis Toxicity 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 3
- DVORYMAGXQGBQK-UHFFFAOYSA-N zhankuic acid A Natural products CC12CCC(=O)C(C)C1CC(=O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 DVORYMAGXQGBQK-UHFFFAOYSA-N 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 241000386860 Cinnamomum micranthum Species 0.000 description 2
- ONFPYGOMAADWAT-OXUZYLMNSA-N Dehydroeburicoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)CC[C@@]4(C)C3=CC[C@H]21 ONFPYGOMAADWAT-OXUZYLMNSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 2
- 0 [1*]CC1=C([Y][2*])C(O)C(C/C=C(\C)CCC=C(C)C)C([3*])C1=O Chemical compound [1*]CC1=C([Y][2*])C(O)C(C/C=C(\C)CCC=C(C)C)C([3*])C1=O 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 229960003750 ethyl chloride Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229930009674 sesquiterpene lactone Natural products 0.000 description 2
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 229930188837 zhankuic acid Natural products 0.000 description 2
- NDNKBYRXHKLSJQ-UXYVAYPWSA-N (2r)-2-[(3s,5r,10s,13r,14r,15s,17r)-15-acetyloxy-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)C[C@H](OC(C)=O)[C@@]4(C)C3=CC[C@H]21 NDNKBYRXHKLSJQ-UXYVAYPWSA-N 0.000 description 1
- DVORYMAGXQGBQK-HPRYJKPLSA-N (2s,6r)-2-methyl-3-methylidene-6-[(4s,5s,10s,13r,14r,17r)-4,10,13-trimethyl-3,7,11-trioxo-1,2,4,5,6,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]heptanoic acid Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)[C@H](C)C(O)=O)C)CC[C@H]21 DVORYMAGXQGBQK-HPRYJKPLSA-N 0.000 description 1
- TWISSXUWVGIUBP-UHFFFAOYSA-N (4alpha,7beta)-7-Hyddroxy-4-methyl-3,11-dioxoergosta-8,24(28)-dien-26-oic acid Natural products CC12CCC(=O)C(C)C1CC(O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 TWISSXUWVGIUBP-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- NDNKBYRXHKLSJQ-UHFFFAOYSA-N 15alpha-acetyldehydrosulphurenic acid Natural products CC(C)C(=C)CCC(C1CC(OC(=O)C)C2(C)C3=CCC4C(C)(C)C(O)CCC4(C)C3=CCC12C)C(=O)O NDNKBYRXHKLSJQ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- WTSUWKBKPMVEBO-UHFFFAOYSA-N 4alpha-4-Methyl-3,11-dioxoergosta-8,24(28)-dien-26-oic acid Natural products CC12CCC(=O)C(C)C1CCC1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 WTSUWKBKPMVEBO-UHFFFAOYSA-N 0.000 description 1
- WAAWMJYYKITCGF-WTPIMUJOSA-N 5alpha-ergostane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C)C(C)C)[C@@]2(C)CC1 WAAWMJYYKITCGF-WTPIMUJOSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 241000123370 Antrodia Species 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 206010004664 Biliary fibrosis Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- LJTSIMVOOOLKOL-NXGXIAAHSA-N COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O Chemical compound COC1=C(OC)C(O)C(C/C=C(\C)CC/C=C(\C)CCC=C(C)C)C(C)C1=O LJTSIMVOOOLKOL-NXGXIAAHSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 238000008998 Catalase assay kit Methods 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 241000386927 Cinnamomum micranthum f. kanehirae Species 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- ONFPYGOMAADWAT-UHFFFAOYSA-N Dehydroeburicolic acid Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)CCC4(C)C3=CCC21 ONFPYGOMAADWAT-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 238000008999 Glutathione Peroxidase assay kit Methods 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 244000227633 Ocotea pretiosa Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000222383 Polyporales Species 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 238000008997 Superoxide Dismutase Assay Kit Methods 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TXEJUZMIQVTZHO-UHFFFAOYSA-N Zhankuic acid B Natural products CC12CCC(O)C(C)C1CC(=O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 TXEJUZMIQVTZHO-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 229930191713 antcin Natural products 0.000 description 1
- WTSUWKBKPMVEBO-QNMMDLTMSA-N antcin A Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1CCC1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)[C@H](C)C(O)=O)C)CC[C@H]21 WTSUWKBKPMVEBO-QNMMDLTMSA-N 0.000 description 1
- TWISSXUWVGIUBP-IRXLFGEOSA-N antcin C Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)[C@H](C)C(O)=O)C)CC[C@H]21 TWISSXUWVGIUBP-IRXLFGEOSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000743 anti-peroxide Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- DVXFDXIVWQWLIU-UHFFFAOYSA-N dehydroeburiconic acid Natural products CC1(C)C(=O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)CCC4(C)C3=CCC21 DVXFDXIVWQWLIU-UHFFFAOYSA-N 0.000 description 1
- LIVBXKAVLWBDCR-FRRGXQJJSA-N dehydrosulphurenic acid Natural products [H][C@@]1(C[C@H](O)[C@@]2(C)C3=CC[C@]4([H])[C@]([H])(CC[C@H](O)C4(C)C)C3=CC[C@]12C)[C@@H](CCC(=C)C(C)C)C(O)=O LIVBXKAVLWBDCR-FRRGXQJJSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000004730 hepatocarcinogenesis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930183875 methylantcinate Natural products 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003429 steroid acids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- DVORYMAGXQGBQK-QCMFUGJUSA-N zhankuic acid A Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC[C@H]21 DVORYMAGXQGBQK-QCMFUGJUSA-N 0.000 description 1
- TXEJUZMIQVTZHO-JNXQNPAGSA-N zhankuic acid B Chemical compound C([C@@]12C)C[C@@H](O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC[C@H]21 TXEJUZMIQVTZHO-JNXQNPAGSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/02—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains containing only carbon and hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Definitions
- the present invention relates to a liver protection compound, in particular to a cyclohexenone compound isolated and purified from Antrodia camphorata extracts, which can be applied in liver protection and alleviation of liver injury and fibrosis.
- the liver is the largest and most complicated organ of metabolism in the body, which is responsible for metabolizing fats, carbohydrates, proteins, vitamins, hormones, and bile. Besides, it has abilities of secretion, excretion, biological transformation and the like. Liver is also an important barrier organ where the detoxification is important to protect the organism. Damaged liver function can cause impaired metabolism, which may affect the function of other organs or can lead to death when serious.
- the prevalence of liver diseases is quite high in Taiwan. According to the Department of Health in Taiwan, chronic liver disease and liver cirrhosis ranked the sixth among the top ten causes of death for Taiwan people, and caused more than 3000 death per year. The rate is still increasing. Therefore, development of liver protection substances, further to prevent or treat liver related diseases, is crucial at present.
- Antrodia camphorata is also called Chang-Zhi, Niu Chang-Zhi, red camphor mushroom and the like, which is a perennial mushroom belonging to the order Aphyllophorales, the family Polyporaceae. It is an endemic species in Taiwan growing on the inner rotten heart wood wall of Cinnamomum kanehirae Hay. Cinnamoum kanehirai Hay is rarely distributed and being overcut unlawfully, which makes Antrodia camphorata growing inside the tree in the wild became even rare. The price of Antrodia camphorata is very expensive due to the extremely slow growth rate of natural Antrodia camphorata that only grows between Junes to October.
- the fruiting bodies of Antrodia camphorata are perennial, sessile, hard and woody, which exhales strong smell of sassafras (camphor aroma).
- the appearances are various with plate-like, bell-like, hoof-like, or tower-like shapes. They are reddish in color and flat when young, attached to the surface of wood. Then the brims of the front end become little curled tilted and extend to the surroundings. The color turns to be faded red-brown or cream yellow brown, with ostioles all over. This region is of very high medical value.
- Antrodia camphorata is commonly used as an antidotal, liver protective, anti-cancer drug.
- Antrodia camphorata like general edible and medicinal mushrooms, is rich in numerous nutrients including polysaccharides (such as ⁇ -glucosan), triterpenoids, superoxide dismutase (SOD), adenosine, proteins (immunoglobulins), vitamins (such as vitamin B, nicotinic acid), trace elements (such as calcium, phosphorus and germanium and so on), nucleic acid, agglutinin, amino acids, steroids, lignins and stabilizers for blood pressure (such as antodia acid) and the like.
- polysaccharides such as ⁇ -glucosan
- SOD superoxide dismutase
- adenosine proteins
- proteins immunoglobulins
- vitamins such as vitamin B, nicotinic acid
- trace elements such as calcium, phosphorus and germanium and so on
- physiologically active ingredients are believed to exhibit effects such as: anti-tumor activities, increasing immuno-modulating activities, anti-allergy, anti-bacteria, anti-high blood pressure, decreasing blood sugar, decreasing cholesterol, liver protection, anti-fatigue, and the like.
- Triterpenoids are the most studied component among the numerous compositions of Antrodia camphorata. Triterpenoids are the summary terms for natural compounds, which contain 30 carbon atoms with the pent acyclic or hex acyclic structures. The bitter taste of Antrodia camphorata is from the component of triterpenoids. Three novel ergostane-type triterpenoids (antcin A, antcin B, antcin C) were isolated by Cherng et al. from the fruiting bodies of Antrodia camphorata (Cherng, I. H., and Chiang, H. C. 1995. Three new triterpenoids from Antrodia cinnamomea. J. Nat. Prod. 58:365-371).
- Antrodia camphorata extracts were reported to have the abovementioned effects from previous experiments, and the components were analyzed in succession, further experiments are needed to identify the effective composition for liver protection.
- the application in liver diseases treatment and prevention of components from Antrodia camphorata extracts will be of great beneficial effects from studies of liver protection if the real effective composition is found.
- the compound of the formula (1) was isolated and purified in the present invention.
- a preferred compound of the general formula (1) is 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone as shown in formula (2), with molecular formula of C 24 H 38 O 4 , appearance of pale yellow powder and molecular weight of 390.
- Cyclohexenone compounds having the structures of formula (1) and formula (2) are purified from aqueous extraction or organic solvent extraction of Antrodia camphorata.
- the organic solvents used include, but not limited to, alcohols such as methanol, ethanol or propanol, esters such as ethyl acetate, alkanes such as hexane, or halogenated alkanes such as chloromethane, chloroethane.
- alcohol is preferred, and ethanol is particularly preferred.
- Cyclohexenone compounds of formula (1) and formula (2) according to the present invention are applied in liver protection and alleviation of liver injury and fibrosis. Feeding cyclohexenone to carbon tetrachloride (CCl 4 ) treated rats helped to alleviate the progress of rat liver injury and fibrosis. The levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were decreased to achieve liver protection ability.
- ALT alanine aminotransferase
- AST aspartate aminotransferase
- cyclohexenone from Antrodia camphorata helped to increase glutathione peroxidase (GSHPx) and antioxidant enzymes catalase (CAT) in the liver in order to decrease the liver cell injury and lower the oxidative pressure induced by free radicals, further to increase antioxidant ability.
- GSHPx glutathione peroxidase
- CAT antioxidant enzymes catalase
- the compounds of formula (1) and/or formula (2) in the present invention can be incorporated into pharmaceutical compositions for treating liver injury to improve the symptoms induced by liver injury in mammals such as human.
- the pharmaceutical compositions include not only the compounds of formula (1) and/or formula (2), but also the pharmaceutically accepted carries.
- examples of such carriers include, but are not limited to, excipients such as water, fillers such as sucrose or starch, binders such as cellulose derivatives, diluents, disintegrants, absorption enhancers or sweeteners.
- compositions can be manufactured through mixing the compounds of formula (1) and/or formula (2) with at least one of the carriers by means of conventional methods known in the pharmaceutically technical field, which can be formulated in the form of, but are not limited to, powder, tablets, capsules, pellets, granules or other liquid formulation.
- FIG. 1 The body weights of rats from each group. *: normal control (gp. A); ⁇ : model control (gp. B, animals receiving 20% CCl 4 ); ⁇ : positive control (gp. C, animals receiving 20% CCl 4 and silymarin); ⁇ : animals receiving 20% CCl 4 and 300 mg/kg cyclohexenone (gp. D); ⁇ : animals receiving 20% CCl 4 and 1000 mg/kg cyclohexenone (gp. E), and ⁇ : animals receiving 20% CCl 4 and 3000 mg/kg cyclohexenone (gp. F).
- FIG. 2 The amounts of food intake in rats from each group. : normal control (gp. A); ⁇ : model control (gp. B, animals receiving 20% CCl 4 ); ⁇ : positive control (gp. C, animals receiving 20% CCl 4 and silymarin); : animals receiving 20% CCl 4 and 300 mg/kg cyclohexenone (gp. D); ⁇ : animals receiving 20% CCl 4 and 1000 mg/kg cyclohexenone (gp. E), and ⁇ : animals receiving 20% CCl 4 and 3000 mg/kg cyclohexenone (gp. F).
- FIG. 3 The pathological changes of the liver surface observed with naked eyes in rats from each group.
- A normal control (gp. A, corn oil only);
- B model control (gp. B, animals receiving 20% CCl 4 );
- C positive control (gp. C, animals receiving 20% CCl 4 and 200 mg/kg silymarin);
- D animals receiving 20% CCl 4 and 300 mg/kg cyclohexenone (gp. D);
- E animals receiving 20% CCl 4 and 1000 mg/kg cyclohexenone (gp. E), and
- F animals receiving 20% CCl 4 and 3000 mg/kg cyclohexenone (gp. F).
- FIG. 4 The pathological changes of CCl 4 -induced liver injury in rats of the invention.
- A H&E staining, magnified 200-fold
- B H&E staining, magnified 400-fold
- C MT staining of collagen fibers, magnified 100-fold, showing vacuoles, fibrosis with nodules, and formation of cirrhosis.
- FIG. 5 The pathological changes of liver fibrosis in rats before or after CCl 4 induction with MT staining on collagen fibers.
- A normal liver tissue;
- B various extents of liver fibrosis and proliferation of collagen after CCl 4 treatment;
- C incomplete septa between central vein and periportal region after CCl 4 treatment;
- D intact septal fibrosis and bridging, many nodules in liver, the septa is thin;
- E complete thick septa, definite cirrhosis after CCl 4 treatment;
- F liver fibrosis and green collagen after CCl 4 treatment.
- F 100-fold magnification.
- the mycelia, fruiting bodies or mixture of both from Antrodia camphorata are first extracted with water or organic solvents to obtain the aqueous extract or organic solvent extract of Antrodia camphorata using the methods well known in the arts.
- the organic solvents include, but not limited to, alcohols such as methanol; ethanol or propanol; esters such as ethyl acetate; alkanes such as hexane; or halogenated alkanes such as chloromethane, and chloroethane. Among them, alcohol is preferred, and ethanol is particularly preferred.
- the aqueous or organic solvent extracts of Antrodia camphorate were subjected to high-performance liquid chromatography (HPLC) for isolation and purification. Each fraction was recovered and applied to liver protection assay. The potent fractions with liver protective ability were analyzed for the composition and further assayed with related biochemical tests for alleviating liver injury. The above approach then led to the identification of compounds of formula (1) and formula (2) in liver protection by alleviating liver injury.
- liver protective ability of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone is explained below as an example for the present invention.
- Liver protective ability of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone were assessed by evaluating the extent of liver injury in liver fibrosis with analysis of the markers of liver injury such as ALT, AST, glutathione (GSH), glutathione peroxidase (GSHPx), catalase (CAT), superoxide dismutase (SOD) after feeding various dosages of cyclohexenone from Antrodia camphorata on chronic liver injury of rats induced by carbon tetrachloride.
- the filtrate of Antrodia camphorata was subjected to High Performance Liquid chromatography (HPLC) analysis.
- HPLC High Performance Liquid chromatography
- the separation was performed on a RP18 column, the mobile phase consisted of methanol (A) and 0.1-0.5% acetic acid (B), with the gradient conditions of 0-10 min in 95% ⁇ 20% B, 10-20 min in 20% ⁇ 10% B, 20-35 min in 10% ⁇ 10% B, 35-40 min in 10% ⁇ 95% B, at the flow rate of 1 ml/min.
- the column effluent was monitored with a UV-visible detector.
- the main causes for liver disease include virus, alcohol and chemicals.
- Chemical induced liver injury in rats exhibits consistent features in pathological section of human liver injury.
- the liver protection assessment in this study is focused on chemical induced liver injury.
- the effects of cyclohexenone from Antrodia camphorata on chronic liver injury of rats were evaluated through the biochemical assays of liver injury and the liver tissue section based on the chronic liver injury model of rats induced by carbon tetrachloride.
- Carbon tetrachloride (CCl 4 ) causes hepatocellular necrosis, further to fibrosis and cirrhosis if not be withdrawn.
- the toxicity of carbon tetrachloride is activated in the liver by the cytochrome P-450 system.
- the initial metabolite is the trichloromethyl radical (.CCl 3 ), which binds with protein to inhibit the protein synthesis, induces imbalanced lipid metabolism with the outcome of triglyceride accumulation.
- the peroxyl product of .CCl 3 induced a lipid peroxidation and damages of cell membrane in the liver, which causes liver enzyme secretion and cell necrosis.
- the animal model of liver injury induced by carbon tetrachloride has similarity to human liver cirrhosis. Therefore, the model can be applied in evaluation of the therapy effects of drugs or food compositions. The details of the procedures are described below.
- the animal model was performed with five-week-old Sprague-Dawley (SD) rats purchased from BioLasco Taiwan Co., Ltd. Healthy rats weighing 220-270 g were chosen for experiment after observing for 2 weeks in the laboratory animal room.
- the rats were randomly divided into 6 groups (12 rats/group): normal (gp. A); control groups including model control (gp. B) and positive control (gp. C, animals receiving silymarin); treatment groups including animals receiving 300 mg/kg of cyclohexenone (gp. D), 1000 mg/kg of cyclohexenone (gp. E), and 3000 mg/kg of cyclohexenone (gp. F), as indicated in Table 1. Only normal group was not poisoned with CCl 4 .
- Silymarin the flavonoid extracted from milk thistle
- Silymarin has been shown to help decrease the liver inflammation and promote healing. It helps to remove toxins from liver cells by either neutralizing the toxicity of toxic compounds or competing with the binding sites in liver. It is a potent antioxidant, protects the liver from free radicals. It has been widely studied for treating various types of liver injury in animals and clinical trials. The beneficial effects on liver protection have made silymarin a good medicine for liver diseases and a drug in positive control group for the animal model of liver injury.
- Rats in normal group (group A) were fed with corn oil (Sigma chemical co.) by means of stomach tubes.
- Carbon tetrachloride (Shimakyu, Osaka, Japan) was administered to groups B to F via stomach tubes twice weekly (every Tuesday and Thursday afternoon) for 8 weeks, at a dose of 2 ml/kg of body weight, diluted with corn oil.
- Silymarin was prepared with saline in an amount of 200 mg/kg of body weight and was fed to rats of group C via a stomach tube.
- Cyclohexenone prepared from example 1 was mixed with saline, and fed in the amounts of 300 mg/kg, 1000 mg/kg and 3000 mg/kg of body weight to rats of group D to F via stomach tubes.
- the total feeding volume was estimated in the ratio of 10 ml/kg of body weight to groups C to F five days a week (every morning) for 8 weeks.
- the body weights of rats and the amounts of food intake in rats for each group were shown in FIG. 1 and FIG. 2 , respectively.
- FIG. 1 shows the body weight changes of rats during 8 weeks of experiment in control groups and treatment groups.
- the weight of rats decreased in all CCl 4 -treated groups except rats in normal group after one week of experiment though the weights in the beginning were not significantly different among groups.
- the body weights of rats in model group (gp. B, 366.9 g), were remarkably lower than those in normal group (gp. A, 448.7 g), at the 8 th week of experiment.
- the treatment of CCl 4 resulted in pathological changes in rats, which caused the decrease of body weight.
- rats fed with silymarin positive control, gp. C
- the body weights did not drop sharply when silymarin was administered. While rats fed with cyclohexenone from Antrodia camphorata in the amount of 300 mg/kg, 1000 mg/kg, and 3000 mg/kg showed weights of 386.6 g, 365.1 g and 355.0 g, respectively. This represented the feeding of cyclohexenone from Antrodia camphorata could effectively alleviate the weight decrease situation when receiving cyclohexenone at the amount of as low as 300 mg/kg of body weight.
- FIG. 2 shows the amounts of food intake during 8 weeks of experiment in control groups and treatment groups.
- the food intake increased during the first to the 5 th week of experiment, while the intake dropped and showed decreasing trends in each group after the 5 th week.
- Treatment of CCl 4 could affect the food intake.
- liver, spleen, and kidney to body weight ratio (%) from model group is significantly higher than those from the normal group.
- CCl 4 has shown to cause pathological changes in these organs by increasing the weights. The increases from silymarin treated group are less than those of model group since silymarin has liver protective effects.
- CCl 4 treated rats fed with different amount of cyclohexenone from Antrodia camphorata showed increase in organ to body weight ratio, but the increases are less than those of model group when the amount of cyclohexenone fed was 300 mg/kg or 1000 mg/kg.
- liver fibrosis The pathological changes of the liver surface were examined with naked eyes when the liver was taken out from rats, and then tissue sections were made. Half of each liver lobe was stored at ⁇ 80° C. for antioxidant enzyme assay to follow up. The rest of liver tissues were fixed in 10% formalin for one week, embedded in paraffin cut into 2 ⁇ m sections, and stained with Hematoxyline-eosin (H&E) to visualize the lipid deposition, inflammation, cell necrosis and fibrosis, or stained with Masson's trichromic solution to visualize extracellular matrix and collagen fibers for liver fibrosis development. The pathological changes of liver injury were evaluated under light microscope (Opticphot-2, Nikon, Tokyo, Japan) after stained with the abovementioned solution.
- H&E Hematoxyline-eosin
- Liver fibrosis was evaluated semiquantitatively according to the scoring methods from Gabriele et al. (Gabriele, B. 1997. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26: 643-649) and Wang et al. (Wang, G. S., Eriksson, L. C., Xia, L., Olsson, J. and Stal, P. 1999. Dietary iron overload inhibits carbon tetrachloride-induced promotion in chemical hepatocarcinogenesis: effects on cell proliferation, apoptosis, and antioxidation. J. Hepatol. 30(4):689-98.).
- Fibrosis was staged on a 0-4 scale: level 0, no fibrosis, normal liver tissue; level 1, proliferation of collagen, portal fibrosis without septa (proliferation of radiating fiber in central vein or periportal region); level 2, incomplete septa between central vein and periportal region (septa without bridging); level 3, intact septal fibrosis and bridging, many nodules in liver, the septa is thin; and level 4, complete thick septa, definite cirrhosis. The results are shown in FIG. 3 to FIG. 5 , and Table 3.
- FIG. 3 shows the pathological changes of the liver surface observed with naked eyes from each group.
- the liver surface was smooth ( FIG. 3A ); while in the CCl 4 -treated model group, the liver was yellow in color, with rough, uneven and tough surface and swelling conditions ( FIG. 3B ).
- rats receiving silymarin or various amounts of cyclohexenone from Antrodia camphorata the extents of liver pathological changes were significantly weaker than that of model group ( FIG. 3C-FIG . 3 F), though showing swelling and pathological conditions.
- rats fed with cyclohexenone in the amount of 3000 mg/kg body weight showed the slightest condition in swelling and pathological conditions ( FIG. 3F ). It shows that cyclohexenone from Antrodia camphorata can effectively improve the surface injury symptoms induced by CCl 4 in liver surfaces.
- FIG. 4 shows the pathological changes of liver injury induced by CCl 4 .
- the liver was swollen in tissue sections, with abundant mitotic division and increased numbers of Kuffer cells ( FIG. 4A and FIG. 4B ). Vacuoles appeared, many nodules were found, and resulted in liver cirrhosis in serious conditions ( FIG. 4C ).
- the liver of the model group showed obvious and the most serious liver injury condition, mainly in moderate to remarkable levels with a score of 3.2 according to Jonker et al. (Table 4).
- Silymarin on CCl 4 induced liver injury had a score of 2.8, while the extents of liver injury in all treatment groups fed with various amounts of cyclohexenone from Antrodia camphorata were improved.
- the remarkable effects were shown in dosages of 300 mg/kg and 1000 mg/kg, mainly distributed in slight to moderate levels with scores of 1.8 and 2.0, respectively.
- FIG. 5 shows the pathological changes of CCl 4 -induced liver fibrosis in rats.
- Normal liver shows no fibrosis, and belongs to level 0 according to Gabriele et al. (1997) and Wang et al. (1999) ( FIG. 5A ); while various fibrosis levels were shown after CCl 4 induction: level 1, proliferation of collagen, portal fibrosis without septa (proliferation of radiating fiber in central vein or periportal region) ( FIG. 5B ); level 2, incomplete septa between central vein and periportal region (septa without bridging) ( FIG. 5C ); level 3, intact septal fibrosis and bridging, many nodules in liver, the septa is thin ( FIG.
- FIG. 5D The collagen in liver appeared to be green after Masson's trichromc staining ( FIG. 5F ).
- the liver of the model group showed the most serious liver fibrosis condition, mainly in level 3 and level 4 with a score of 3.2 (Table 3).
- Silymarin on CCl 4 induced liver fibrosis had a score of 2.8, while the extents of liver fibrosis in all treatment groups fed with various amounts of cyclohexenone from Antrodia camphorata were improved.
- the remarkable effect was shown on the dosage of 300 mg/kg, mainly distributed in level 1 to level 2 with a score of 1.8.
- ALT and AST are important enzymes in amino acid synthesis for human organs such as liver, heart, muscle and the like. These enzymes maintain low contents in serum under normal condition with levels of 40 U/L for ALT and 50 U/L for AST.
- the increase in serum ALT and AST release are associated with inflammation of cells from the abovementioned organs, which are caused by the change of cell permeability or cell rupture. Therefore the levels of ALT and AST are good indicators for liver inflammation and liver injury.
- CCl 4 The levels of ALT, AST and cholesterol in the CCl 4 -treated model group were all higher than those in the normal group. CCl 4 has shown to cause liver injury, which led to the increase in enzyme activities. The cholesterol level also increased but not much. The increases in ALT, AST and cholesterol from silymarin fed positive control group are less than those of model group since silymarin has liver protective effects. On the other hand, CCl 4 treated rats fed with different amount of cyclohexenone from Antrodia camphorata showed higher levels in ALT, AST and cholesterol than those of normal group, but the increases are all significantly less than those of model group (p ⁇ 0.05).
- Antioxidant enzyme system including glutathione (GSH), glutathione peroxidase (GSHPx), catalase (CAT), superoxide dismutase (SOD) and the like plays a great role in protecting organisms from oxidative damage and decrease oxidative stress when free radicals increase.
- This experiment detected the contents of antioxidant enzymes after CCl 4 induced liver injury in rats and evaluated the antioxidant ability of cyclohexenone from Antrodia camphorata.
- liver stored at ⁇ 80° C. as described above was immersed in PBS buffer (phosphate buffered saline solution, pH 7.4) containing 0.16 mg/ml heparin. Red blood cells were removed from the tissue. Liver was prepared as 1.0 g tissue/10 mL buffer homogenates in fresh, chilled 50 mM phosphate, 1 mM EDTA (pH 6-7) buffer using a Polytron homogenizer (setting 5, PT 10 probe, Brinkmann Instruments, Westbury, N.Y.) for one min. The solution was centrifuged at 10,000 ⁇ g for 15 min at 4° C.
- PBS buffer phosphate buffered saline solution, pH 7.4
- Red blood cells were removed from the tissue. Liver was prepared as 1.0 g tissue/10 mL buffer homogenates in fresh, chilled 50 mM phosphate, 1 mM EDTA (pH 6-7) buffer using a Polytron homogenizer (setting 5, PT 10 probe, Brinkmann Instruments, Westbury, N
- Protein concentration was determined with a BCA protein assay kit (Pierce, Ill., USA) at 550 nm using an enzyme linked immunosorbent assay (ELISA) reader (MAX ELISA Reader, Quant, Bio-Tek Instrument, Vermont, USA).
- ELISA enzyme linked immunosorbent assay
- Commercial kits of glutathione (GSH), glutathione peroxidase (GSHPx), catalase (CAT), superoxide dismutase (SOD) Glutathione Assay Kit, Cat No. 703002; Glutathione Peroxidase Assay Kit, Cat No. 703102; Catalase Assay Kit, Cat No. 707002; Superoxide Dismutase Assay Kit, Cat No.
- GSH Glutathione activity (uM/mg protein); GSHPx: glutathione peroxidase activity (nmol/min/ml) one unit is defined as the amount of enzyme that will cause the oxidation of 1 nmol of NADPH to NADPH + per minute at 25° C.; Catalase and SOD: U/mg protein 1 All values were expressed as mean ⁇ SD using MS-Excels program. *P ⁇ 0.05, showing a significant difference between normal group and other tested groups after analyzed with Student t-test. a P ⁇ 0.05, showing a significant difference between model group and other tested groups after analyzed with Student t-test.
- the levels of antioxidant enzymes in the CCl 4 -treated model group were not significant different from those in the normal group; the levels in silymarin fed positive control group were also not significant different from those either in the normal group or in the model group.
- the SOD level in group D (the 300 mg/kg cyclohexenone fed group) were significantly lower than all other groups.
- the GSHPx and CAT levels in group E (the 1000 mg/kg cyclohexenone fed group) and F group (the 3000 mg/kg cyclohexenone fed group) were higher than other groups. Both the GSHPx and CAT are able to decompose hydrogen peroxide to non-toxic water to prevent the damage caused by peroxides. Therefore cyclohexenone from Antrodia camphorata can decrease the damage of free radicals, reduce the oxidative pressure further to enhance the antioxidant ability by increasing the contents of GSHPx and CAT.
- the compound 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone isolated from Antrodia camphorata can be used to effectively decrease the extents of liver injury and liver fibrosis induced by chemicals.
- the inflammation indicators of ALT and AST were also reduced.
- cyclohexenone further decreases the liver damage and the oxidative pressure caused by free radicals, enhances the antioxidant ability and achieves the purposed of liver protection.
- cyclohexenone from Antrodia camphorata is a natural extract, which won't induce uncomfortable side effects, toxicity or complications when applied in treating liver injury or liver protection. It also contains anti-free radical function such as anti-peroxides, which makes it beneficial to human health by preventing liver injury when prepared as health supplements, drinks and the like. In addition, it can be incorporated into pharmaceutical compositions.
- the pharmaceutical compositions include not only the active compound 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone, but also the pharmaceutically accepted carries.
- Such carriers include, but are not limited to, excipients such as water, fillers such as sucrose or starch, binders such as cellulose derivatives, diluents, disintegrants, absorption enhancers or sweeteners.
- the pharmaceutical composition can be manufactured through mixing the compound of cyclohexenone from Antrodia camphorata with at least one of the carriers by means of conventional methods known in the pharmaceutically technical field, which can be formulated in the forms of powder, tablets, capsules, pellets, granules or other liquid formulation, but are not limited to. The purpose for prevention and treatment of liver injury and liver protection can then be accomplished.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a compound of Antrodia camphorata used for liver protection, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone which is isolated from Antrodia camphorate. The cyclohexenone compound according to the invention helps to alleviate liver injury and fibrosis induced by chemicals and reduces the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). By increasing the contents of glutathione peroxidase (GSHPX) and catalase (CAT), cyclohexenone further decreases the liver damage and the oxidative pressure caused by free radicals, enhances the antioxidant ability and achieves the purposed of liver protection.
Description
- 1. Field of the Invention
- The present invention relates to a liver protection compound, in particular to a cyclohexenone compound isolated and purified from Antrodia camphorata extracts, which can be applied in liver protection and alleviation of liver injury and fibrosis.
- 2. The Prior Arts
- The liver is the largest and most complicated organ of metabolism in the body, which is responsible for metabolizing fats, carbohydrates, proteins, vitamins, hormones, and bile. Besides, it has abilities of secretion, excretion, biological transformation and the like. Liver is also an important barrier organ where the detoxification is important to protect the organism. Damaged liver function can cause impaired metabolism, which may affect the function of other organs or can lead to death when serious. The prevalence of liver diseases is quite high in Taiwan. According to the Department of Health in Taiwan, chronic liver disease and liver cirrhosis ranked the sixth among the top ten causes of death for Taiwan people, and caused more than 3000 death per year. The rate is still increasing. Therefore, development of liver protection substances, further to prevent or treat liver related diseases, is crucial at present.
- Antrodia camphorata is also called Chang-Zhi, Niu Chang-Zhi, red camphor mushroom and the like, which is a perennial mushroom belonging to the order Aphyllophorales, the family Polyporaceae. It is an endemic species in Taiwan growing on the inner rotten heart wood wall of Cinnamomum kanehirae Hay. Cinnamoum kanehirai Hay is rarely distributed and being overcut unlawfully, which makes Antrodia camphorata growing inside the tree in the wild became even rare. The price of Antrodia camphorata is very expensive due to the extremely slow growth rate of natural Antrodia camphorata that only grows between Junes to October.
- The fruiting bodies of Antrodia camphorata are perennial, sessile, hard and woody, which exhales strong smell of sassafras (camphor aroma). The appearances are various with plate-like, bell-like, hoof-like, or tower-like shapes. They are reddish in color and flat when young, attached to the surface of wood. Then the brims of the front end become little curled tilted and extend to the surroundings. The color turns to be faded red-brown or cream yellow brown, with ostioles all over. This region is of very high medical value.
- In traditional Taiwanese medicine, Antrodia camphorata is commonly used as an antidotal, liver protective, anti-cancer drug. Antrodia camphorata, like general edible and medicinal mushrooms, is rich in numerous nutrients including polysaccharides (such as β-glucosan), triterpenoids, superoxide dismutase (SOD), adenosine, proteins (immunoglobulins), vitamins (such as vitamin B, nicotinic acid), trace elements (such as calcium, phosphorus and germanium and so on), nucleic acid, agglutinin, amino acids, steroids, lignins and stabilizers for blood pressure (such as antodia acid) and the like. These physiologically active ingredients are believed to exhibit effects such as: anti-tumor activities, increasing immuno-modulating activities, anti-allergy, anti-bacteria, anti-high blood pressure, decreasing blood sugar, decreasing cholesterol, liver protection, anti-fatigue, and the like.
- Triterpenoids are the most studied component among the numerous compositions of Antrodia camphorata. Triterpenoids are the summary terms for natural compounds, which contain 30 carbon atoms with the pent acyclic or hex acyclic structures. The bitter taste of Antrodia camphorata is from the component of triterpenoids. Three novel ergostane-type triterpenoids (antcin A, antcin B, antcin C) were isolated by Cherng et al. from the fruiting bodies of Antrodia camphorata (Cherng, I. H., and Chiang, H. C. 1995. Three new triterpenoids from Antrodia cinnamomea. J. Nat. Prod. 58:365-371). Three new compounds zhankuic acid A, zhankuic acid B and zhankuic acid were extracted from the fruiting bodies of Antrodia camphorata with ethanol by Chen et al. (Chen, C. H., and Yang, S. W. 1995. New steroid acids from Antrodia cinnamomea,—a fungus parasitic on Cinnamomum micranthum. J. Nat. Prod. 58:1655-1661). In addition, Cherng et al. also found three other new triterpenoids from the fruiting bodies of Antrodia camphorata, which are sesquiterpene lactone and 2 biphenyl derived compounds, 4,7-dimethoxy-5-methy-1,3-benzodioxole and 2,2′,5,5′-teramethoxy-3,4,3′,4′-bi-methylenedioxy-6,6′-dimethylbiphenyl (Chiang, H. C., Wu, D. P., Chemg, I. W., and Ueng, C. H. 1995. A sesquiterpene lactone, phenyl and biphenyl compounds from Antrodia cinnamomea. Phytochemistry. 39:613-616). In 1996, four novel ergostane-type triterpenoids (antcins E and F and methyl antcinates G and H) were isolated by Chemg et al. with the same analytic methods (Chemg, I. H., Wu, D. P., and Chiang, H. C. 1996. Triteroenoids from Antrodia cinnamomea. Phytochemistry. 41:263-267). And two ergostane related steroids, zhankuic acids D and E together with three lanosta related triterpenes, 15 alpha-acetyl-dehydrosulphurenic acid, dehydroeburicoic acid, dehydrosulphurenic acid were isolated by Yang et al. (Yang, S. W., Shen, Y. C., and Chen, C. H. 1996. Steroids and triterpenoids of Antrodia cinnamomea—a fungus parasitic on Cinnamomum micranthum. Phytochemistry. 41:1389-1392).
- Although Antrodia camphorata extracts were reported to have the abovementioned effects from previous experiments, and the components were analyzed in succession, further experiments are needed to identify the effective composition for liver protection. The application in liver diseases treatment and prevention of components from Antrodia camphorata extracts will be of great beneficial effects from studies of liver protection if the real effective composition is found.
- In order to identify which are the compounds to prevent or treat liver diseases from the extracts of Antrodia camphorata, the compound of the formula (1) was isolated and purified in the present invention,
- wherein X and Y can be oxygen or sulfur, R1, R2 and R3 are each a hydrogen atom, methyl or (CH2)m—CH3 and m=1-12; n=1-12.
- A preferred compound of the general formula (1) is 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone as shown in formula (2), with molecular formula of C24H38O4, appearance of pale yellow powder and molecular weight of 390.
- Cyclohexenone compounds having the structures of formula (1) and formula (2) are purified from aqueous extraction or organic solvent extraction of Antrodia camphorata. The organic solvents used include, but not limited to, alcohols such as methanol, ethanol or propanol, esters such as ethyl acetate, alkanes such as hexane, or halogenated alkanes such as chloromethane, chloroethane. Among them, alcohol is preferred, and ethanol is particularly preferred.
- Cyclohexenone compounds of formula (1) and formula (2) according to the present invention are applied in liver protection and alleviation of liver injury and fibrosis. Feeding cyclohexenone to carbon tetrachloride (CCl4) treated rats helped to alleviate the progress of rat liver injury and fibrosis. The levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were decreased to achieve liver protection ability. In addition, cyclohexenone from Antrodia camphorata helped to increase glutathione peroxidase (GSHPx) and antioxidant enzymes catalase (CAT) in the liver in order to decrease the liver cell injury and lower the oxidative pressure induced by free radicals, further to increase antioxidant ability.
- On the other hand, the compounds of formula (1) and/or formula (2) in the present invention can be incorporated into pharmaceutical compositions for treating liver injury to improve the symptoms induced by liver injury in mammals such as human. The pharmaceutical compositions include not only the compounds of formula (1) and/or formula (2), but also the pharmaceutically accepted carries. Examples of such carriers include, but are not limited to, excipients such as water, fillers such as sucrose or starch, binders such as cellulose derivatives, diluents, disintegrants, absorption enhancers or sweeteners. The compositions can be manufactured through mixing the compounds of formula (1) and/or formula (2) with at least one of the carriers by means of conventional methods known in the pharmaceutically technical field, which can be formulated in the form of, but are not limited to, powder, tablets, capsules, pellets, granules or other liquid formulation.
- The present invention is further explained in the following embodiment illustration and examples. Those examples below should not, however, be considered to limit the scope of the invention, it is contemplated that modifications will readily occur to those skilled in the art, which modifications will be within the spirit of the invention and the scope of the appended claims.
- The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the office upon request and payment of the necessary fee.
-
FIG. 1 The body weights of rats from each group. *: normal control (gp. A); □: model control (gp. B, animals receiving 20% CCl4); □: positive control (gp. C, animals receiving 20% CCl4 and silymarin); ▪: animals receiving 20% CCl4 and 300 mg/kg cyclohexenone (gp. D); ▴: animals receiving 20% CCl4 and 1000 mg/kg cyclohexenone (gp. E), and : animals receiving 20% CCl4 and 3000 mg/kg cyclohexenone (gp. F). -
FIG. 2 The amounts of food intake in rats from each group. : normal control (gp. A); Δ: model control (gp. B, animals receiving 20% CCl4); □: positive control (gp. C, animals receiving 20% CCl4 and silymarin); : animals receiving 20% CCl4 and 300 mg/kg cyclohexenone (gp. D); ▴: animals receiving 20% CCl4 and 1000 mg/kg cyclohexenone (gp. E), and : animals receiving 20% CCl4 and 3000 mg/kg cyclohexenone (gp. F). -
FIG. 3 The pathological changes of the liver surface observed with naked eyes in rats from each group. (A) normal control (gp. A, corn oil only); (B) model control (gp. B, animals receiving 20% CCl4); (C) positive control (gp. C, animals receiving 20% CCl4 and 200 mg/kg silymarin); (D) animals receiving 20% CCl4 and 300 mg/kg cyclohexenone (gp. D); (E) animals receiving 20% CCl4 and 1000 mg/kg cyclohexenone (gp. E), and (F) animals receiving 20% CCl4 and 3000 mg/kg cyclohexenone (gp. F). -
FIG. 4 The pathological changes of CCl4-induced liver injury in rats of the invention. (A) H&E staining, magnified 200-fold; (B) H&E staining, magnified 400-fold; (C) MT staining of collagen fibers, magnified 100-fold, showing vacuoles, fibrosis with nodules, and formation of cirrhosis. -
FIG. 5 The pathological changes of liver fibrosis in rats before or after CCl4 induction with MT staining on collagen fibers. (A) normal liver tissue; (B) various extents of liver fibrosis and proliferation of collagen after CCl4 treatment; (C) incomplete septa between central vein and periportal region after CCl4 treatment; (D) intact septal fibrosis and bridging, many nodules in liver, the septa is thin; (E) complete thick septa, definite cirrhosis after CCl4 treatment; (F) liver fibrosis and green collagen after CCl4 treatment. (A) to (E): 40-fold magnification; (F) 100-fold magnification. - The mycelia, fruiting bodies or mixture of both from Antrodia camphorata are first extracted with water or organic solvents to obtain the aqueous extract or organic solvent extract of Antrodia camphorata using the methods well known in the arts. The organic solvents include, but not limited to, alcohols such as methanol; ethanol or propanol; esters such as ethyl acetate; alkanes such as hexane; or halogenated alkanes such as chloromethane, and chloroethane. Among them, alcohol is preferred, and ethanol is particularly preferred.
- The aqueous or organic solvent extracts of Antrodia camphorate were subjected to high-performance liquid chromatography (HPLC) for isolation and purification. Each fraction was recovered and applied to liver protection assay. The potent fractions with liver protective ability were analyzed for the composition and further assayed with related biochemical tests for alleviating liver injury. The above approach then led to the identification of compounds of formula (1) and formula (2) in liver protection by alleviating liver injury.
- The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the formula (2) is explained below as an example for the present invention. Liver protective ability of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone were assessed by evaluating the extent of liver injury in liver fibrosis with analysis of the markers of liver injury such as ALT, AST, glutathione (GSH), glutathione peroxidase (GSHPx), catalase (CAT), superoxide dismutase (SOD) after feeding various dosages of cyclohexenone from Antrodia camphorata on chronic liver injury of rats induced by carbon tetrachloride.
- These assays have proved that 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone from Antrodia camphorata can be used to alleviate liver injury and fibrosis caused by chemicals. The levels of inflammatory markers ALT and AST were decreased, the levels of GSHPx and CAT in the liver were increased in order to decrease the liver cell injury and lower the oxidative pressure induced by free radicals, further to increase antioxidant ability of the liver. The details of the examples are described as follows:
- One hundred grams of mycelia, fruiting bodies or mixture of both from Antrodia camphorata were placed into a flask. A proper amount of water and alcohol (70-100% alcohol solution) was added into the flask and were stirred at 20-25° C. for at least 1 hour. The solution was filtered through a filter and a 0.45 μm membrane and the filtrate was collected as the extract.
- The filtrate of Antrodia camphorata was subjected to High Performance Liquid chromatography (HPLC) analysis. The separation was performed on a RP18 column, the mobile phase consisted of methanol (A) and 0.1-0.5% acetic acid (B), with the gradient conditions of 0-10 min in 95%˜20% B, 10-20 min in 20%˜10% B, 20-35 min in 10%˜10% B, 35-40 min in 10%˜95% B, at the flow rate of 1 ml/min. The column effluent was monitored with a UV-visible detector.
- The fractions collected at 25-30 min were collected and concentrated to yield 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone, a product of pale yellow powder. The analysis of 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone showed the molecular formula of C24H38O4, molecular weight of 390, melting point of 48° C.˜52° C. Investigation of NMR spectra showed that 1H-NMR(CDCl3) δ (ppm)=1.51, 1.67, 1.71, 1.75, 1.94, 2.03, 2.07, 2.22, 2.25, 3.68, 4.05, 5.07, and 5.14; 13C-NMR(CDCl3) δ (ppm)=12.31, 16.1, 16.12, 17.67, 25.67, 26.44, 26.74, 27.00, 39.71, 39.81, 4.027, 43.34, 59.22, 60.59, 120.97, 123.84, 124.30, 131.32, 135.35, 135.92, 138.05, 160.45, and 197.12.
- Liver Protection Tests with Cyclohexenone of Antrodia camphorata
- The main causes for liver disease include virus, alcohol and chemicals. Chemical induced liver injury in rats exhibits consistent features in pathological section of human liver injury. The liver protection assessment in this study is focused on chemical induced liver injury. The effects of cyclohexenone from Antrodia camphorata on chronic liver injury of rats were evaluated through the biochemical assays of liver injury and the liver tissue section based on the chronic liver injury model of rats induced by carbon tetrachloride. Carbon tetrachloride (CCl4) causes hepatocellular necrosis, further to fibrosis and cirrhosis if not be withdrawn. The toxicity of carbon tetrachloride is activated in the liver by the cytochrome P-450 system. The initial metabolite is the trichloromethyl radical (.CCl3), which binds with protein to inhibit the protein synthesis, induces imbalanced lipid metabolism with the outcome of triglyceride accumulation. The peroxyl product of .CCl3 induced a lipid peroxidation and damages of cell membrane in the liver, which causes liver enzyme secretion and cell necrosis. As cited above, the animal model of liver injury induced by carbon tetrachloride has similarity to human liver cirrhosis. Therefore, the model can be applied in evaluation of the therapy effects of drugs or food compositions. The details of the procedures are described below.
- The animal model was performed with five-week-old Sprague-Dawley (SD) rats purchased from BioLasco Taiwan Co., Ltd. Healthy rats weighing 220-270 g were chosen for experiment after observing for 2 weeks in the laboratory animal room. The rats were randomly divided into 6 groups (12 rats/group): normal (gp. A); control groups including model control (gp. B) and positive control (gp. C, animals receiving silymarin); treatment groups including animals receiving 300 mg/kg of cyclohexenone (gp. D), 1000 mg/kg of cyclohexenone (gp. E), and 3000 mg/kg of cyclohexenone (gp. F), as indicated in Table 1. Only normal group was not poisoned with CCl4. The body weights were recorded to calculate the dosage. Silymarin, the flavonoid extracted from milk thistle, has been shown to help decrease the liver inflammation and promote healing. It helps to remove toxins from liver cells by either neutralizing the toxicity of toxic compounds or competing with the binding sites in liver. It is a potent antioxidant, protects the liver from free radicals. It has been widely studied for treating various types of liver injury in animals and clinical trials. The beneficial effects on liver protection have made silymarin a good medicine for liver diseases and a drug in positive control group for the animal model of liver injury.
-
TABLE 1 The experimental groups with the substances fed and the dosages 20%(v/v) Group CCl4 cyclohexenone silymarin A (normal) 0 0 0 Control B ( model 2 ml/ kg BW 0 0 groups control) C (positive 2 ml/ kg BW 0 200 mg/kg control) Treat- D 2 ml/ kg BW 300 mg/ kg 0 ment E 2 ml/kg BW 1000 mg/ kg 0 group F 2 ml/kg BW 3000 mg/ kg 0 - Rats in normal group (group A) were fed with corn oil (Sigma chemical co.) by means of stomach tubes. Carbon tetrachloride (Shimakyu, Osaka, Japan) was administered to groups B to F via stomach tubes twice weekly (every Tuesday and Thursday afternoon) for 8 weeks, at a dose of 2 ml/kg of body weight, diluted with corn oil. Silymarin was prepared with saline in an amount of 200 mg/kg of body weight and was fed to rats of group C via a stomach tube. Cyclohexenone prepared from example 1 was mixed with saline, and fed in the amounts of 300 mg/kg, 1000 mg/kg and 3000 mg/kg of body weight to rats of group D to F via stomach tubes. The total feeding volume was estimated in the ratio of 10 ml/kg of body weight to groups C to F five days a week (every morning) for 8 weeks. The body weights of rats and the amounts of food intake in rats for each group were shown in
FIG. 1 andFIG. 2 , respectively. -
FIG. 1 shows the body weight changes of rats during 8 weeks of experiment in control groups and treatment groups. The weight of rats decreased in all CCl4-treated groups except rats in normal group after one week of experiment though the weights in the beginning were not significantly different among groups. The body weights of rats in model group (gp. B, 366.9 g), were remarkably lower than those in normal group (gp. A, 448.7 g), at the 8th week of experiment. The treatment of CCl4 resulted in pathological changes in rats, which caused the decrease of body weight. In addition, rats fed with silymarin (positive control, gp. C) showed a less decrease in weights as low as 375.8 g than rats in model control group (gp. B). The body weights did not drop sharply when silymarin was administered. While rats fed with cyclohexenone from Antrodia camphorata in the amount of 300 mg/kg, 1000 mg/kg, and 3000 mg/kg showed weights of 386.6 g, 365.1 g and 355.0 g, respectively. This represented the feeding of cyclohexenone from Antrodia camphorata could effectively alleviate the weight decrease situation when receiving cyclohexenone at the amount of as low as 300 mg/kg of body weight. -
FIG. 2 shows the amounts of food intake during 8 weeks of experiment in control groups and treatment groups. The food intake increased during the first to the 5th week of experiment, while the intake dropped and showed decreasing trends in each group after the 5th week. Treatment of CCl4 could affect the food intake. - All rats were sacrificed at the end of the 8th week of experiment. The weights of liver, kidney and spleen were recovered and weighted and compared with the body weights to calculate the ratios and observe the effects of cyclohexenone from Antrodia camphorata to CCl4 treatment. All values are expressed as mean±SD, which were evaluated using One-way Analysis of Variance. Those with significant differences were further tested with the Least Signnificant Difference Test (LSD) or Student t-test to compare cyclohexenone treatment groups and normal groups, positive control and model groups. P<0.05 was selected as criterion for statistical significance in all cases. The results are shown in Table 2.
-
TABLE 2 The effect of cyclohexenone from Antrodia camphorata to the weights of organs in rats after CCl4-induced liver injury spleen kidney liver Group (%) (%) (%) A (normal) 0.16 ± 0.03 0.62 ± 0.06 2.68 ± 0.33 B (model control, 0.25 ± 0.08* 0.76 ± 0.11* 3.30 ± 0.54* 20% CCl4) C (positive control, 0.22 ± 0.05* 0.71 ± 0.08* 3.43 ± 0.63* silymarin) Treatment groups Cyclohexenone from Antrodia camphorata (mg/kg) D. 300 mg/kg 0.20 ± 0.05* 0.68 ± 0.06* 3.29 ± 0.35 E. 1000 mg/kg 0.22 ± 0.06* 0.69 ± 0.13 3.20 ± 0.47* F. 3000 mg/kg 0.30 ± 0.10* 0.73 ± 0.08* 3.65 ± 0.53* 1) All values were expressed as mean ± SD using MS-Excels program. *P < 0.05, showing a significant difference between normal group and other tested groups after analyzed with Student t-test. a: P < 0.05, showing a significant difference between model group and other tested groups after analyzed with Student t-test. - Each of the liver, spleen, and kidney to body weight ratio (%) from model group is significantly higher than those from the normal group. CCl4 has shown to cause pathological changes in these organs by increasing the weights. The increases from silymarin treated group are less than those of model group since silymarin has liver protective effects. On the other hand, CCl4 treated rats fed with different amount of cyclohexenone from Antrodia camphorata showed increase in organ to body weight ratio, but the increases are less than those of model group when the amount of cyclohexenone fed was 300 mg/kg or 1000 mg/kg. These results show beneficial effect of cyclohexenone from Antrodia camphorata in CCl4 treated rats since the organ weights were not consistently increased.
- The pathological changes of the liver surface were examined with naked eyes when the liver was taken out from rats, and then tissue sections were made. Half of each liver lobe was stored at −80° C. for antioxidant enzyme assay to follow up. The rest of liver tissues were fixed in 10% formalin for one week, embedded in paraffin cut into 2 μm sections, and stained with Hematoxyline-eosin (H&E) to visualize the lipid deposition, inflammation, cell necrosis and fibrosis, or stained with Masson's trichromic solution to visualize extracellular matrix and collagen fibers for liver fibrosis development. The pathological changes of liver injury were evaluated under light microscope (Opticphot-2, Nikon, Tokyo, Japan) after stained with the abovementioned solution.
- Assessment of pathologic score in the chronic liver damage, the extent of inflammation, vacuolar degeneration, liver cell necrosis and bile duct proliferation were graded semi-quantitatively on a “0” to “4” scale (
level 0=−, none,level 1=+, slight,level 2=++, mild,level 3=+++, moderate, andlevel 4=++++, remarkable, according to Jonker et al. (Jonker, A. M., Dijkhuis, F. W., Boes, A., Hardonk, M. J. and Grond J. 1992. Immunohistochemical study of extracellular matrix in acute galactosamine hepatitis in rats. Hepatology. 15(3):423-31). - Liver fibrosis was evaluated semiquantitatively according to the scoring methods from Gabriele et al. (Gabriele, B. 1997. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26: 643-649) and Wang et al. (Wang, G. S., Eriksson, L. C., Xia, L., Olsson, J. and Stal, P. 1999. Dietary iron overload inhibits carbon tetrachloride-induced promotion in chemical hepatocarcinogenesis: effects on cell proliferation, apoptosis, and antioxidation. J. Hepatol. 30(4):689-98.). Fibrosis was staged on a 0-4 scale:
level 0, no fibrosis, normal liver tissue;level 1, proliferation of collagen, portal fibrosis without septa (proliferation of radiating fiber in central vein or periportal region);level 2, incomplete septa between central vein and periportal region (septa without bridging);level 3, intact septal fibrosis and bridging, many nodules in liver, the septa is thin; andlevel 4, complete thick septa, definite cirrhosis. The results are shown inFIG. 3 toFIG. 5 , and Table 3. -
FIG. 3 shows the pathological changes of the liver surface observed with naked eyes from each group. In the normal group, the liver surface was smooth (FIG. 3A ); while in the CCl4-treated model group, the liver was yellow in color, with rough, uneven and tough surface and swelling conditions (FIG. 3B ). After rats receiving silymarin or various amounts of cyclohexenone from Antrodia camphorata, the extents of liver pathological changes were significantly weaker than that of model group (FIG. 3C-FIG . 3F), though showing swelling and pathological conditions. Among them, rats fed with cyclohexenone in the amount of 3000 mg/kg body weight showed the slightest condition in swelling and pathological conditions (FIG. 3F ). It shows that cyclohexenone from Antrodia camphorata can effectively improve the surface injury symptoms induced by CCl4 in liver surfaces. -
TABLE 3 Histological evaluation of CCl4 induced liver injury in rats from different group Liver injury Liver fibrosis − + ++ +++ ++++ score − + ++ +++ ++++ score Group A (normal) 125) — — — — 0.0 12 — — — — 0.0 B (model control, — — 2 3 4 3.2* — — 2 3 4 3.2* 20% CCl4) C (positive control, — 2 1 4 3 2.8* — 2 1 5 3 2.8* silymarin) Treatment groups Cyclohexenone from Antrodia camphorata (mg/kg) D. 300 mg/kg — 5 6 — 1 1.8*a — 6 4 1 1 1.8*a E. 1000 mg/kg — 3 6 1 1 2.0*a 2 1 4 3 1 2.0*a F. 3000 mg/kg — 2 6 1 2 2.3*a — 2 4 3 2 2.5* 1) Assessment of pathologic score in the chronic liver damage, the extent of inflammation, vacuolar degeneration, liver cell necrosis and bile duct proliferation were graded semi-quantitatively according to Jonker et al. 1992 on a “0” to “4” scale (level 0 = −, none, level 1 = +, slight, level 2 = ++, mild, level 3 = +++, moderate, and level 4 = ++++, remarkable). 2) Chronic liver injury score in rats = counts of pathological rats/total counts of rats. 3) Fibrosis was staged according to Gabriele et al. (1997) and Wang et al. (1999) on a 0-4 scale: level 0, no fibrosis, normal liver tissue;level 1, proliferation of collagen, portal fibrosis without septa (proliferation of radiating fiber in central vein or periportal region);level 2, incomplete septa between central vein and periportal region (septa without bridging);level 3, intact septal fibrosis and bridging, many nodules in liver, the septa is thin; andlevel 4, complete thick septa, definite cirrhosis.4) Liver fibrosis score in rats = counts of pathological rats/total counts of rats. 5)Counts of pathological rats. *P < 0.05, showing a significant difference between normal group and other tested groups after analyzed with Student t-test. aP < 0.05, showing a significant difference between model group and other tested groups after analyzed with Student t-test. - Referring to
FIG. 4 and Table 3,FIG. 4 shows the pathological changes of liver injury induced by CCl4. The liver was swollen in tissue sections, with abundant mitotic division and increased numbers of Kuffer cells (FIG. 4A andFIG. 4B ). Vacuoles appeared, many nodules were found, and resulted in liver cirrhosis in serious conditions (FIG. 4C ). The liver of the model group showed obvious and the most serious liver injury condition, mainly in moderate to remarkable levels with a score of 3.2 according to Jonker et al. (Table 4). Silymarin on CCl4 induced liver injury had a score of 2.8, while the extents of liver injury in all treatment groups fed with various amounts of cyclohexenone from Antrodia camphorata were improved. The remarkable effects were shown in dosages of 300 mg/kg and 1000 mg/kg, mainly distributed in slight to moderate levels with scores of 1.8 and 2.0, respectively. - Referring to
FIG. 5 and Table 3,FIG. 5 shows the pathological changes of CCl4-induced liver fibrosis in rats. Normal liver shows no fibrosis, and belongs tolevel 0 according to Gabriele et al. (1997) and Wang et al. (1999) (FIG. 5A ); while various fibrosis levels were shown after CCl4 induction:level 1, proliferation of collagen, portal fibrosis without septa (proliferation of radiating fiber in central vein or periportal region) (FIG. 5B );level 2, incomplete septa between central vein and periportal region (septa without bridging) (FIG. 5C );level 3, intact septal fibrosis and bridging, many nodules in liver, the septa is thin (FIG. 5D ); andlevel 4, complete thick septa, definite cirrhosis (FIG. 5E ). The collagen in liver appeared to be green after Masson's trichromc staining (FIG. 5F ). The liver of the model group showed the most serious liver fibrosis condition, mainly inlevel 3 andlevel 4 with a score of 3.2 (Table 3). Silymarin on CCl4 induced liver fibrosis had a score of 2.8, while the extents of liver fibrosis in all treatment groups fed with various amounts of cyclohexenone from Antrodia camphorata were improved. The remarkable effect was shown on the dosage of 300 mg/kg, mainly distributed inlevel 1 tolevel 2 with a score of 1.8. - These results show beneficial effects of cyclohexenone from Antrodia camphorata in CCl4 treated rats in liver injury and liver fibrosis. CCl4 treated rats fed with different amount of cyclohexenone from Antrodia camphorata all showed better effects than silymarin. And the best effect was found on the dosage of 300 mg/kg.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are important enzymes in amino acid synthesis for human organs such as liver, heart, muscle and the like. These enzymes maintain low contents in serum under normal condition with levels of 40 U/L for ALT and 50 U/L for AST. The increase in serum ALT and AST release are associated with inflammation of cells from the abovementioned organs, which are caused by the change of cell permeability or cell rupture. Therefore the levels of ALT and AST are good indicators for liver inflammation and liver injury.
- All rats were sacrificed at the end of the 8th week of experiment, blood samples were collected from abdominal aorta for assessing liver biochemical parameters. Five ml of blood were transferred to a tube and centrifuged at 775×g for 15 min. 0.5 ml of serum was analyzed on an Express plus automatic clinical chemistry analyzer (Chiron diagnostics corporation, OH, USA) with commercial kits of ALT (Bayer diagnostics, Cat No. E36941), AST (Bayer diagnostics, Cat No. E37041) and cholesterol (Bayer diagnostics, Cat No. E33940). All values are expressed as mean±SD, which were evaluated using One-way Analysis of Variance. Those with significant differences were further tested with the Least Signnificant Difference Test (LSD) or Student t-test to compare cyclohexenone treatment groups and normal groups, positive control and model groups. P<0.05 was selected as criterion for statistical significance in all cases. The results are shown in Table 4.
-
TABLE 4 Indicators of liver function of CCl4 induced liver injury in rats from different group ALT AST Cholesterol Group (U/L) (U/L) (mg/dL) A (normal) 50.7 ± 9.11) 110.9 ± 25.1 63.8 ± 12.2 B (model control, 453.4 ± 201.8* 470.4 ± 310.1* 66.7 ± 8.7 20% CCl4) C (positive control, 180.8 ± 94.6* a 249.5 ± 105.0* a 69.5 ± 14.3 Silymarin) Treatment groups Cyclohexenone from Antrodia camphorata (mg/kg) D. 300 mg/kg 226.6 ± 138.7* a 323.4 ± 189.0* 63.7 ± 15.1 E. 1000 mg/kg 181.7 ± 78.4* a 283.2 ± 144.2* 69.6 ± 14.8 F. 3000 mg/kg 206.0 ± 98.4* a 311.7 ± 99.6* 62.1 ± 16.2 1)All values were expressed as mean ± SD using MS-Excels program. *P < 0.05, showing a significant difference between normal group and other tested groups after analyzed with Student t-test. a: P < 0.05, showing a significant difference between model group and other tested groups after analyzed with Student t-test. - The levels of ALT, AST and cholesterol in the CCl4-treated model group were all higher than those in the normal group. CCl4 has shown to cause liver injury, which led to the increase in enzyme activities. The cholesterol level also increased but not much. The increases in ALT, AST and cholesterol from silymarin fed positive control group are less than those of model group since silymarin has liver protective effects. On the other hand, CCl4 treated rats fed with different amount of cyclohexenone from Antrodia camphorata showed higher levels in ALT, AST and cholesterol than those of normal group, but the increases are all significantly less than those of model group (p<0.05). The decreases of ALT and AST in comparison to the model group in the 1000 mg/kg cyclohexenone treatment group were the most obvious (ALT:181.7±78.4 U/L, and AST:283.2±144.2 U/L). These results show that 300 mg/kg, 1000 mg/kg and 3000 mg/kg cyclohexenone from Antrodia camphorata can effectively decrease the release of ALT and AST on CCl4 treated rats.
- Antioxidant enzyme system including glutathione (GSH), glutathione peroxidase (GSHPx), catalase (CAT), superoxide dismutase (SOD) and the like plays a great role in protecting organisms from oxidative damage and decrease oxidative stress when free radicals increase. This experiment detected the contents of antioxidant enzymes after CCl4 induced liver injury in rats and evaluated the antioxidant ability of cyclohexenone from Antrodia camphorata.
- The liver stored at −80° C. as described above was immersed in PBS buffer (phosphate buffered saline solution, pH 7.4) containing 0.16 mg/ml heparin. Red blood cells were removed from the tissue. Liver was prepared as 1.0 g tissue/10 mL buffer homogenates in fresh, chilled 50 mM phosphate, 1 mM EDTA (pH 6-7) buffer using a Polytron homogenizer (setting 5, PT 10 probe, Brinkmann Instruments, Westbury, N.Y.) for one min. The solution was centrifuged at 10,000×g for 15 min at 4° C. Protein concentration was determined with a BCA protein assay kit (Pierce, Ill., USA) at 550 nm using an enzyme linked immunosorbent assay (ELISA) reader (MAX ELISA Reader, Quant, Bio-Tek Instrument, Vermont, USA). Commercial kits of glutathione (GSH), glutathione peroxidase (GSHPx), catalase (CAT), superoxide dismutase (SOD) (Glutathione Assay Kit, Cat No. 703002; Glutathione Peroxidase Assay Kit, Cat No. 703102; Catalase Assay Kit, Cat No. 707002; Superoxide Dismutase Assay Kit, Cat No. 706002) were purchased from Cayman Chemical Company (MI.USA) and assayed by reading at 405 nm, 340 nm, 540 nm and 450 nm using an ELISA reader. Deprotein step was carried out for all the assays mention above except SOD assay. Proteins were precipitated by mixing with equal volume of 10% metaphosphoric acid (w/v), vortex-mixed evenly, centrifuged at 2,000×g for 2 min. The supernatant was removed for enzyme assay. All values are expressed as mean±SD, which were evaluated using One-way Analysis of Variance. Those with significant differences were further tested with the Least Signnificant Difference Test (LSD) or Student t-test to compare cyclohexenone treatment groups and normal groups, positive control and model groups. P<0.05 was selected as criterion for statistical significance in all cases. The results are shown in Table 5.
-
TABLE 5 Effects of cyclohexenone from Antrodia camphorata on antioxidant enzymes to the CCl4 treated, liver injury model animals GSH GSHPx Catalase SOD (uM/mg (nmol/ (U/mg (U/mg Group protein) min/ml) protein) protein) A (normal) 31.5 ± 3.81 11.4 ± 2.8 8.9 ± 1.4 0.65 ± 0.22 B (model 31.5 ± 6.5 9.9 ± 2.5 9.6 ± 1.6 0.80 ± 0.41 control, 20% CCl4) C (positive 30.5 ± 4.1 9.6 ± 3.0 9.2 ± 1.4 0.68 ± 0.23 control, Silymarin) Treatment groups Cyclohexenone from Antrodia camphorata (mg/kg) D. 300 mg/kg 30.3 ± 3.2 9.6 ± 1.7 9.1 ± 1.0 0.47 ± 0.17*a E. 1000 mg/kg 25.2 ± 1.8*a 11.2 ± 3.4 10.1 ± 1.4* 0.52 ± 0.28 F. 3000 mg/kg 26.7 ± 4.3*a 10.6 ± 3.1 9.8 ± 0.9 0.73 ± 0.23 GSH: Glutathione activity (uM/mg protein); GSHPx: glutathione peroxidase activity (nmol/min/ml) one unit is defined as the amount of enzyme that will cause the oxidation of 1 nmol of NADPH to NADPH+ per minute at 25° C.; Catalase and SOD: U/mg protein 1All values were expressed as mean ± SD using MS-Excels program. *P < 0.05, showing a significant difference between normal group and other tested groups after analyzed with Student t-test. aP < 0.05, showing a significant difference between model group and other tested groups after analyzed with Student t-test. - Referring to Table 5, the levels of antioxidant enzymes in the CCl4-treated model group were not significant different from those in the normal group; the levels in silymarin fed positive control group were also not significant different from those either in the normal group or in the model group. Relatively, the SOD level in group D (the 300 mg/kg cyclohexenone fed group) were significantly lower than all other groups. The GSHPx and CAT levels in group E (the 1000 mg/kg cyclohexenone fed group) and F group (the 3000 mg/kg cyclohexenone fed group) were higher than other groups. Both the GSHPx and CAT are able to decompose hydrogen peroxide to non-toxic water to prevent the damage caused by peroxides. Therefore cyclohexenone from Antrodia camphorata can decrease the damage of free radicals, reduce the oxidative pressure further to enhance the antioxidant ability by increasing the contents of GSHPx and CAT.
- In summary, the compound 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone isolated from Antrodia camphorata according to the present invention can be used to effectively decrease the extents of liver injury and liver fibrosis induced by chemicals. The inflammation indicators of ALT and AST were also reduced. By increasing the contents of GSHPx and CAT, cyclohexenone further decreases the liver damage and the oxidative pressure caused by free radicals, enhances the antioxidant ability and achieves the purposed of liver protection. On the other hand, cyclohexenone from Antrodia camphorata is a natural extract, which won't induce uncomfortable side effects, toxicity or complications when applied in treating liver injury or liver protection. It also contains anti-free radical function such as anti-peroxides, which makes it beneficial to human health by preventing liver injury when prepared as health supplements, drinks and the like. In addition, it can be incorporated into pharmaceutical compositions. The pharmaceutical compositions include not only the active compound 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone, but also the pharmaceutically accepted carries. Examples of such carriers include, but are not limited to, excipients such as water, fillers such as sucrose or starch, binders such as cellulose derivatives, diluents, disintegrants, absorption enhancers or sweeteners. The pharmaceutical composition can be manufactured through mixing the compound of cyclohexenone from Antrodia camphorata with at least one of the carriers by means of conventional methods known in the pharmaceutically technical field, which can be formulated in the forms of powder, tablets, capsules, pellets, granules or other liquid formulation, but are not limited to. The purpose for prevention and treatment of liver injury and liver protection can then be accomplished.
Claims (21)
1. A method for liver protection which comprises
administering to a subject in need thereof an effective amount of a cyclohexenone compound of Antrodia camphorata having the following formula:
wherein X and Y is oxygen or sulfur, R1, R2 and R3 are each a hydrogen atom, methyl or (CH2)m−CH3, and m=1-12; n=1-12;
2. The method as claimed in claim 1 , wherein the compound is isolated from the organic solvent extracts of Antrodia camphorata.
3. The method as claimed in claim 2 , wherein the organic solvents are selected from the group consisting of alcohols, esters, alkanes, and halogenated alkanes.
4. The method as claimed in claim 3 , wherein the alcohol is ethanol.
5. The method as claimed in claim 1 , wherein the compound is isolated from the aqueous extracts of Antrodia camphorata.
6. The method as claimed in claim 1 , wherein the compound is 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone.
7. The method according to claim 1 , wherein the compound can prevent and alleviate liver injury and fibrosis in mammals.
8. The method according to claim 6 , wherein the compound can prevent and alleviate liver injury and fibrosis in mammals.
9. The method as claimed in claim 7 , wherein the amount of the compound to be administered is in the range of 300-3000 mg/kg body weight.
10. The method as claimed in claim 8 , wherein the amount of the compound to be administered is in the range of 300-3000 mg/kg body weight.
11. The method as claimed in claim 7 , wherein the mammal is a human.
12. The method as claimed in claim 8 , wherein the mammal is a human.
13. The method as claimed in claim 7 , wherein the liver injury is caused by chemical compounds.
14. The method as claimed in claim 8 , wherein the liver injury is caused by chemical compounds.
15. The method as claimed in claim 13 , wherein the chemical compound is carbon tetrachloride (CCl4).
16. The method as claimed in claim 14 , wherein the chemical compound is carbon tetrachloride (CCl4).
17. The method as claimed in claim 7 , wherein the compound protects liver by inhibiting the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
18. The method as claimed in claim 8 , wherein the compound protects liver by inhibiting the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
19. The method as claimed in claim 7 , wherein the compound alleviates the liver injury induced by free radicals through increasing the levels of glutathione peroxidase (GSHPx) and catalase (CAT).
20. The method as claimed in claim 8 , wherein the compound alleviates the liver injury induced by free radicals through increasing the levels of glutathione peroxidase (GSHPx) and catalase (CAT).
21-22. (canceled)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW096121548A TWI394573B (en) | 2007-06-14 | 2007-06-14 | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection |
TW096121548 | 2007-06-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
US7456225B1 US7456225B1 (en) | 2008-11-25 |
US20080312335A1 true US20080312335A1 (en) | 2008-12-18 |
Family
ID=39048353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/902,599 Expired - Fee Related US7456225B1 (en) | 2007-06-14 | 2007-09-24 | Liver protection compounds of the cyclohexenone type from Antrodia camphorata |
Country Status (7)
Country | Link |
---|---|
US (1) | US7456225B1 (en) |
JP (1) | JP2008308479A (en) |
KR (1) | KR101069959B1 (en) |
DE (1) | DE102007049063A1 (en) |
FR (1) | FR2917407B1 (en) |
GB (1) | GB2450189B (en) |
TW (1) | TWI394573B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110123562A1 (en) * | 2009-11-26 | 2011-05-26 | Chiang Been-Huang | Anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof |
WO2012100228A3 (en) * | 2011-01-21 | 2012-11-22 | Golden Biotechnology Corporation | Methods and compositions for treating kidney disorders |
WO2014158242A1 (en) * | 2013-03-13 | 2014-10-02 | Golden Biotechnology Corporation | Method for the treatment of fatty liver disease |
US20150080477A1 (en) * | 2012-03-26 | 2015-03-19 | Golden Biotechnology Corporation | Methods and compositions for treating arteriosclerotic vascular diseases |
CN109069448A (en) * | 2016-02-17 | 2018-12-21 | 国鼎生物科技股份有限公司 | For treating the composition and method of liver cancer |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI394573B (en) * | 2007-06-14 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection |
JP5203644B2 (en) * | 2007-07-13 | 2013-06-05 | 國鼎生物科技股▲ふん▼有限公司 | Compounds derived from Benicus mushroom for use in the treatment of autoimmune diseases |
TWI409073B (en) * | 2010-11-26 | 2013-09-21 | Univ China Medical | Treatment of pain, inflammation and liver injury and hepatoprotection with ergosta-7,9(11),22e-trien-3β-ol |
US9675652B2 (en) | 2011-07-29 | 2017-06-13 | HXLS Charity Corp. | Compositions and methods to relieve chronic diseases symptoms |
CA2892084C (en) * | 2012-11-21 | 2020-11-10 | Golden Biotechnology Corporation | Methods and compositions for treating neurodegenerative diseases |
CN104115669B (en) * | 2013-04-27 | 2016-11-02 | 富裔实业股份有限公司 | Antrodia camphorata cultural method and the preparation method of Antrodia camphorata wine extraction thing |
US9789153B2 (en) | 2014-07-02 | 2017-10-17 | Hsiu-Hsien Tsai | Composition for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs |
CN104111302A (en) * | 2014-08-13 | 2014-10-22 | 中山安荞生物科技有限公司 | Method for measuring adenosine content of health-protection antrodia food |
CN104940841B (en) * | 2015-07-16 | 2018-06-08 | 北京市平谷区中医医院 | A kind of Chinese medicine composition and application thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1386545A (en) * | 2001-05-18 | 2002-12-25 | 葡萄王企业股份有限公司 | Antrodia camphorata preparation for protecting liver |
US6740517B2 (en) * | 2001-12-14 | 2004-05-25 | Ming-Huang Lan | Incubation method for obtaining solid culture of Zang Zhi, solid culture obtained therefrom, processed products and use thereof |
JP5403844B2 (en) * | 2004-03-02 | 2014-01-29 | 善笙生物科技股▲分▼有限公司 | Novel mixtures and compounds obtained from the mycelium of AntrodiaCamphorata |
TW200829234A (en) * | 2007-01-08 | 2008-07-16 | Golden Biotechnology Corp | Antrodia camphorata isophorone extract |
TWI394573B (en) * | 2007-06-14 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection |
TWI394575B (en) * | 2007-07-09 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for the Suppression of Hepatitis B |
JP5203644B2 (en) * | 2007-07-13 | 2013-06-05 | 國鼎生物科技股▲ふん▼有限公司 | Compounds derived from Benicus mushroom for use in the treatment of autoimmune diseases |
-
2007
- 2007-06-14 TW TW096121548A patent/TWI394573B/en not_active IP Right Cessation
- 2007-09-14 JP JP2007240271A patent/JP2008308479A/en active Pending
- 2007-09-24 US US11/902,599 patent/US7456225B1/en not_active Expired - Fee Related
- 2007-10-01 KR KR1020070098585A patent/KR101069959B1/en not_active IP Right Cessation
- 2007-10-12 DE DE102007049063A patent/DE102007049063A1/en not_active Ceased
- 2007-10-22 FR FR0758451A patent/FR2917407B1/en not_active Expired - Fee Related
- 2007-12-19 GB GB0724748.9A patent/GB2450189B/en not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110123562A1 (en) * | 2009-11-26 | 2011-05-26 | Chiang Been-Huang | Anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof |
US9950021B2 (en) | 2009-11-26 | 2018-04-24 | National Taiwan University | Anti-cancer active substance from Antrodia camphorata, method for preparing the same and use thereof |
WO2012100228A3 (en) * | 2011-01-21 | 2012-11-22 | Golden Biotechnology Corporation | Methods and compositions for treating kidney disorders |
US10406120B2 (en) | 2011-01-21 | 2019-09-10 | Golden Biotechnology Corporation | Methods and compositions for treating kidney disorders |
US20150080477A1 (en) * | 2012-03-26 | 2015-03-19 | Golden Biotechnology Corporation | Methods and compositions for treating arteriosclerotic vascular diseases |
US10905656B2 (en) * | 2012-03-26 | 2021-02-02 | Golden Biotechnology Corporation | Methods and compositions for treating arteriosclerotic vascular diseases |
WO2014158242A1 (en) * | 2013-03-13 | 2014-10-02 | Golden Biotechnology Corporation | Method for the treatment of fatty liver disease |
CN109069448A (en) * | 2016-02-17 | 2018-12-21 | 国鼎生物科技股份有限公司 | For treating the composition and method of liver cancer |
EP3416630A4 (en) * | 2016-02-17 | 2019-10-09 | Golden Biotechnology Corporation | Compositions and methods for treating liver cancer |
Also Published As
Publication number | Publication date |
---|---|
JP2008308479A (en) | 2008-12-25 |
TWI394573B (en) | 2013-05-01 |
KR20080110444A (en) | 2008-12-18 |
FR2917407A1 (en) | 2008-12-19 |
GB2450189B (en) | 2012-03-21 |
DE102007049063A1 (en) | 2008-12-18 |
US7456225B1 (en) | 2008-11-25 |
GB2450189A (en) | 2008-12-17 |
FR2917407B1 (en) | 2011-07-22 |
TW200848066A (en) | 2008-12-16 |
KR101069959B1 (en) | 2011-10-04 |
GB0724748D0 (en) | 2008-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7456225B1 (en) | Liver protection compounds of the cyclohexenone type from Antrodia camphorata | |
JP5085186B2 (en) | A novel compound isolated from Benix nokitake | |
JP5014959B2 (en) | New compounds isolated from Benix nokitake extract | |
US7501454B2 (en) | Cyclohexenone compounds from Antrodia camphorata to treat autoimmune diseases | |
EP2221291B1 (en) | Cyclohexenone compounds from antrodia camphorata and pharmaceutical compositions thereof useful for treating autoimmune diseases | |
TW200902041A (en) | A cyclohexenones compound extracted from Antrodia camphorata for suppressing hepatitis B virus (HBV) | |
US20110060058A1 (en) | Inhibition of the Survival of Ovarian Cancer by Cyclohexenone Compounds from Antrodia Camphorata | |
TWI444194B (en) | Anti-cancer extract and compounds | |
US8236860B2 (en) | Inhibition of the survival of pancreatic cancer by cyclohexenone compounds from Antrodia camphorata | |
Cao et al. | Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity | |
US20110059123A1 (en) | Inhibition of the Survival of Colorectal Cancer by Cyclohexenone Compounds from Antrodia Camphorata | |
US20110060056A1 (en) | Inhibition of the Survival of Gastric Cancer by Cyclohexenone Compounds from Antrodia Camphorata | |
US20120322890A1 (en) | Inhibition of the Survival of Bone Cancer by Cyclohexenone Compounds from Antrodia Camphorata | |
US20130005825A1 (en) | Inhibition of the Survival of Lymphoma by Cyclohexenone Compounds from Antrodia Camphorata | |
Zarei et al. | The physiological and pharmacological effects of Ziziphoratenuior L.: A review study | |
JP5203644B2 (en) | Compounds derived from Benicus mushroom for use in the treatment of autoimmune diseases | |
US20130005827A1 (en) | Inhibition of the Survival of Bladder Cancer by Cyclohexenone Compounds from Antrodia Camphorata | |
US20120277320A1 (en) | Inhibition of the survival of skin cancer by cyclohexenone compounds from antrodia camphorata | |
CN101376624B (en) | Cinnamomum kanehirae Hayata pimelie kelone compound for liver protection | |
Alshehri | Antidiabetic activity of cissus rotundifolia plant growing in Saudi Arabia | |
US20170273916A1 (en) | Methods for treating and preventing neurodegenerative diseases | |
HU et al. | Comparative study on yield and agronomic traits of different types of oat in western Jilin Province | |
CN107184588B (en) | Application of sterol in reduction of muscle and embryo toxicity of statins | |
TWI409073B (en) | Treatment of pain, inflammation and liver injury and hepatoprotection with ergosta-7,9(11),22e-trien-3β-ol | |
JPWO2007111306A1 (en) | Lipid metabolism improver |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GOLDEN BIOTECHNOLOGY CORPORATION, TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIU, SHENG-YUN;WEN, WU-CHE;KUO, MAO-TIEN;REEL/FRAME:019952/0494 Effective date: 20070917 |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20161125 |